Biopharmaceutical company Pfizer Inc (NYSE:PFE) on Tuesday announced positive top-line data from the Phase 3 MONeT trial evaluating ABRYSVO in adults aged 18-59 at risk of developing severe RSV-associated lower respiratory tract disease (LRTD).
ABRYSVO met primary endpoints, demonstrating non-inferior immune response compared to the Phase 3 RENOIR study in older adults, and was well-tolerated. These findings will be submitted to regulatory agencies to seek approval for adults 18-59.
The study addressed a significant unmet need, focusing on adults with chronic conditions such as asthma and diabetes, who are at increased risk for RSV disease. Results also met diversity recruitment goals, reflecting the US population's diversity and medical conditions.
Pfizer plans to expand ABRYSVO's indication to adults 18 and older subject to regulatory approval.
These findings will be published in a scientific journal and presented at upcoming conferences, potentially positioning ABRYSVO as the first RSV vaccine for adults 18 and older.
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract